Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc.
Advertisement Those interested in taking part in clinical trials for HIV prevention – including the REV UP clinical trial – can contact Sherri Karas Certo by calling or texting 412-818-4942 or ...
A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as ...
Gilead Sciences, Inc. and Tubulis have announced that they have entered into an exclusive option and license agreement to ...
The Daily Digest on MSN2d
Page settings
A new study has found that a twice-yearly injection of lenacapavir can reduce the risk of HIV by 96%.
A new injectable drug for HIV prevention, lenacapavir, is being hailed as a potential game-changer in the fight against the ...
FOX 5 spoke exclusively with a participant in a study for a new injectable drug to prevent HIV. Emory University medical ...
Rwanda is set to roll out the long-acting injectable PrEP known as cabotegravir (CAB-LA). PrEP refers to the use of ...
Courtney Breen, an analyst from Bernstein, has initiated a new Buy rating on Gilead Sciences (GILD).Don't Miss our Black Friday Offers:Unlock ...
The US President's Emergency Plan for AIDS Relief (PEPFAR), the largest global health investment ever by any country to ...
Twice-yearly injectables might soon be available to help prevent HIV infection. The injectable Sunlenca is even more ...
A twice-yearly shot could end AIDS, but will it reach everyone who needs it? Gilead's HIV prevention drug is 100% effective ...